Pegfilgrastim Biosimilars in US Supportive Oncology: A Narrative Review of Administration Options and Economic Considerations to Maximize Patient Benefit
Open Access
- 16 September 2022
- journal article
- review article
- Published by Springer Nature in Oncology and Therapy
- Vol. 10 (2) , 351-361
Abstract
Granulocyte colony-stimulating factor (G-CSF) biologics, such as pegfilgrastim, are a standard of care in supportive cancer treatment that are administered once per chemotherapy cycle to reduce the incidence of febrile neutropenia. The high cost of these biologics in the United States can be a limiting factor to accessing care; however, lower-cost pegfilgrastim biosimilars have been available for several years for patients requiring prophylaxis of febrile neutropenia. Different options for pegfilgrastim administration are also now available to accommodate specific patient preferences. As patients may want to minimize the risk of both neutropenia and SARS-CoV-2 infection, same-day administration is a pertinent option during the present COVID-19 pandemic. Therefore, individualized, patient-centered approaches and risk-management strategies should be considered when selecting the treatment and administration method for prophylaxis of febrile neutropenia. Three methods of administration would minimize hospital or clinic visits while also providing the prophylactic effect of G-CSF: same-day administration after chemotherapy, use of the US Food and Drug Administration–approved on-body injector delivering pegfilgrastim approximately 27 h after chemotherapy, or self-administration by the patient or caregiver > 24 h after chemotherapy. Choice of the specific administration option should be based on the patient’s specific needs, while also considering mitigating factors, such as the economic burden associated with biologic medications and the risk of COVID-19. Pegfilgrastim biosimilars can minimize the additional financial burden on patients and the health care system during this pandemic and beyond.Keywords
This publication has 44 references indexed in Scilit:
- How to help patients achieve correct self-injection techniquePractice Nursing, 2014
- Impact of Financial Burden of Cancer on Survivors' Quality of LifeJournal of Oncology Practice, 2014
- ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European studyMedical Devices: Evidence and Research, 2013
- Clinical experience with Zarzio® in Europe: what have we learned?Supportive Care in Cancer, 2013
- Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)BMC Cancer, 2013
- Elevated cyclin B2 expression in invasive breast carcinoma is associated with unfavorable clinical outcomeBMC Cancer, 2013
- Anaemia management in chronic kidney disease patientsJournal of Renal Nursing, 2012
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Forgoing medical care because of costCancer, 2010
- Are Shorter Courses of Filgrastim Prophylaxis Associated with Increased Risk of Hospitalization?Annals of Pharmacotherapy, 2006